# Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma

> **NCT02337946** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 164 (actual)

## Conditions studied

- Colorectal Carcinoma

## Interventions

- **DRUG:** oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
- **DRUG:** oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab

## Key facts

- **NCT ID:** NCT02337946
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-16
- **Primary completion:** 2017-03-31
- **Final completion:** 2017-08-31
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2019-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02337946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02337946, "Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02337946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*